4-(Tri-n-butylstannyl)pyridine → HCID 57634270, Verbindung
Reaktionsgleichung
Br[C:2]1[S:6][C:5]([N:7]2[CH2:11][C:10]3([CH:16]4[CH2:17][CH2:18][N:13]([CH2:14][CH2:15]4)[CH2:12]3)[O:9][C:8]2=[O:19])=[N:4][CH:3]=1.C([Sn](CCCC)(CCCC)[C:25]1[CH:30]=[CH:29][N:28]=[CH:27][CH:26]=1)CCC>>[N:28]1[CH:29]=[CH:30][C:25]([C:2]2[S:6][C:5]([N:7]3[CH2:11][C:10]4([CH:16]5[CH2:17][CH2:18][N:13]([CH2:14][CH2:15]5)[CH2:12]4)[O:9][C:8]3=[O:19])=[N:4][CH:3]=2)=[CH:26][CH:27]=1Komponenten
3
Versuchsvorschrift
The title compound was prepared by a method analogous to that described in Example 14 from 3′-(5-bromothiazol-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5′-oxazolidin]-2′-one and 4-(tri-n-butylstannyl)pyridine. The title compound (52 mg) was obtained as a pale solid, m/z 343 (MH+).
Aufarbeitung
- customThe title compound was prepared by a method analogous to
Quellen und Nachweise
- ORD-Eintrag
- ord-b5e62e9cfa374de0b7ed3f6289562fd5